Skip to content
← Lobby Directory
IT
OtherIT

Inserm Transfert

Paris, FRANCELtdReg: 190044226228-01Since 23/03/2017

Budget

€50 — €0

EP Access

0

accredited persons

Staff

3

0.45 FTE

EU Grants

€1,547,259

Mission & Goals

Private subsidiary of Inserm, Inserm Transfert manages every aspect of the promotion and transfer of knowledge obtained by Inserm’s research laboratories to industry, thereby helping to promote health innovation. Inserm Transfert focus on adding value and minimizing risk for innovative projects at pre-industrial stage, bridging discovery and clinical research. We put emphasis on identifying high-potential projects, implementing appropriate proof of concept and IP strategies, and setting up win-win/mutually beneficial industrial partnerships.

EU Legislative Interests

EU legislatives proposals or policies pertaining to - Pharmaceutical regulation and medicinal product marketing authorisation, - Research and innovation, - Public health (both human and animal and digital health data)

Interests Represented

Promotes their own interests or the collective interests of their members

Member Of

Inserm Transfert is a member of the - Reseau C.U.R.I.E https://www.curie.asso.fr/reseau-curie/qui-sommes-nous/administrateurs - Association France Biotech https://france-biotech.fr/annuaire/?_annuaire=adherents&_company_name=Inserm%20Transfert - Pascale Augé our CEO is a membre of the network AUTM-Association of University Technology Managers https://autm.net/

Organisation Members

Inserm Transfert is the private subsidiary of the National Institut of Health and Medical research (INSERM) http://www.inserm.fr/inserm-transfert (https://www.inserm-transfert.fr/inserm-transfert-en/our-mission-and-successes/)

Additional Information

EU grants that contribute to the operating costs - We have a department dedicated to project management of EC projects. This department is made up of 25 people namely- Collaborative Research Funding - entirely dedicated since 2003 to support researchers in handling project management and reporting to European Commission. During the most recent closed financial year (2023) our company was a full partner of 34 EU funding projects and recevied prepayment for 23 projects.

Commissioner Meetings

No recorded meetings with EU commissioners.